“Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801: Induction chemotherapy followed by chemoradiotherapy compared with chemor...

Por Stinchcombe, Thomas E., Hodgson, Lydia, Herndon, James E., Kelley, Michael J., Cicchetti, M. Giulia, Ramnath, Nithya, B.Niell, Harvey, Atkins, James N., Akerley, Wallace, Green, Mark. R., Vokes, Everett E.
Publicado em 2009

Endpoints in Phase II trials for advanced non-small cell lung cancer

Por Mandrekar, Sumithra J., Qi, Yingwei, Hillman, Shauna L., Allen Ziegler, Katie L., Reuter, Nicholas F., Rowland, Kendrith M., Kuross, Steven A., Marks, Randolph S., Schild, Steven E., Adjei, Alex A.
Publicado em 2010

Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies

Por Stinchcombe, Thomas E., Socinski, Mark A., Lee, Carrie B., Hayes, D. Neil, Moore, Dominic T., Goldberg, Richard M., Dees, E. Claire
Publicado em 2008

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415)

Por Gold, Philip J., Goldman, Bryan, Iqbal, Syma, Leichman, Lawrence P., Zhang, Wu, Lenz, Heinz-Josef, Blanke, Charles D.
Publicado em 2010

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer

Por Qi, Yingwei, Schild, Steven E., Mandrekar, Sumithra J., Tan, Angelina D., Krook, James E., Rowland, Kendrith M., Garces, Yolanda I., Soori, Gamini S., Adjei, Alex A., Sloan, Jeff A.
Publicado em 2009

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

Por Karp, Daniel D., Pollak, Michael N., Cohen, Roger B., Eisenberg, Peter D., Haluska, Paul, Yin, Donghua, Lipton, Allan, Demers, Laurence, Leitzel, Kim, Hixon, Mary L., Terstappen, Leon W., Garland, Linda, Paz-Ares, Luis G., Cardenal, Felipe, Langer, Corey J., Gualberto, Antonio
Publicado em 2009

Novel EGFR mutation specific antibodies for NSCLC: Immunohistochemistry as a possible screening method for EGFR mutations

Por Kato, Yasufumi, Peled, Nir, Wynes, Murry W., Yoshida, Koichi, Pardo, Marta, Mascaux, Celine, Ohira, Tatsuo, Tsuboi, Masahiro, Matsubayashi, Jun, Nagao, Toshitaka, Ikeda, Norihiko, Hirsch, Fred R.
Publicado em 2010

Evaluation of Glutathione Metabolic Genes on Outcomes in Advanced Non-small Cell Lung Cancer Patients after Initial Treatment with Platinum-Based Chemotherapy: An NCCTG-97-24-51 Ba...

Por Yang, Ping, Mandrekar, Sumithra J., Hillman, Shauna H., Allen Ziegler, Katie L., Sun, Zhifu, Wampfler, Jason A., Cunningham, Julie M., Sloan, Jeff A., Adjei, Alex A., Perez, Edith, Jett, James R.
Publicado em 2009

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-Small-Cell Lung Cancer Treated with or without Bevacizumab in Combination with Pac...

Por Brahmer, Julie R., Dahlberg, Suzanne E., Gray, Robert J., Schiller, Joan H., Perry, Michael C., Sandler, Alan, Johnson, David H.
Publicado em 2011

Prognostic and Predictive value of EGFR Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-Small Cell Lung Cancer

Por Tsao, Ming-Sound, Sakurada, Akira, Ding, Keyue, Aviel-Ronen, Sarit, Ludkovski, Olga, Liu, Ni, Le Maître, Aurélie, Gandara, David, Johnson, David H., Rigas, James R., Seymour, Lesley, Shepherd, Frances A.
Publicado em 2011

Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study

Por Gould, Michael K., Schultz, Ellen M., Wagner, Todd H., Xu, Xiangyan, Ghaus, Sharfun J., Wallace, Robert B., Provenzale, Dawn, Au, David H.
Publicado em 2011

Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models

Por Sun, Yunguang, Moretti, Luigi, Giacalone, Nicholas J, Schleicher, Stephen, Speirs, Christina K., Carbone, David P., Lu, Bo
Publicado em 2011

Lung Cancer Serum Biomarker Discovery Using Label Free LC-MS/MS

Por Zeng, Xuemei, Hood, Brian L., Zhao, Ting, Conrads, Thomas P., Sun, Mai, Gopalakrishnan, Vanathi, Grover, Himanshu, Day, Roger S., Weissfeld, Joel L., Wilson, David O., Siegfried, Jill M., Bigbee, William L.
Publicado em 2011

Systematic evaluation of genetic variants in three biological pathways on patient survival in low stage non-small cell lung cancer

Por Pankratz, V. Shane, Sun, Zhifu, Aakre, Jeremiah, Li, Yan, Johnson, Cassandra, Garces, Yolanda I., Aubry, Marie C, Molina, Julian R., Wigle, Dennis, Yang, Ping
Publicado em 2011

Cost-Effectiveness of CT Screening for Lung Cancer in the U.S.

Por McMahon, Pamela M., Kong, Chung Yin, Bouzan, Colleen, Weinstein, Milton C., Cipriano, Lauren E., Tramontano, Angela C., Johnson, Bruce E., Weeks, Jane C., Gazelle, G. Scott
Publicado em 2011

Bortezomib for Patients with Advanced Stage Bronchioloalveolar Carcinoma (BAC): A California Cancer Consortium Phase II Study (NCI # 7003)

Por Ramalingam, Suresh S., Davies, Angela M., Longmate, Jeffrey, Edelman, Martin J., Lara, Primo N., Vokes, Everett E., Villalona-Calero, Miguel, Gitlitz, Barbara, Reckamp, Karen, Salgia, Ravi, Wright, John J., Belani, Chandra P., Gandara, David R.
Publicado em 2011

Quality of Life and Symptom Burden among Long Term Lung Cancer Survivors: Changing and Adapting

Por Yang, Ping, Cheville, Andrea L., Wampfler, Jason A., Garces, Yolanda I., Jatoi, Aminah, Clark, Matthew M., Cassivi, Stephen D., Midthun, David E., Marks, Randolph S., Aubry, Marie-Christine, Okuno, Scott H., Williams, Brent A., Nichols, Francis C., Trastek, Victor F., Sugimura, Hiroshi, Sarna, Linda, Allen, Mark S., Deschamps, Claude, Sloan, Jeff A.
Publicado em 2012

Aberrant Regulation of the MRP3 Gene in Non-Small Cell Lung Carcinoma

Por Mahaffey, Christopher M., Mahaffey, Nichole C., Holland, William, Zhang, Hongqiao, Gandara, David R., Mack, Philip C., Forman, Henry Jay
Publicado em 2012

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy (CT-RT) for Unresectable Stage IIIA/IIIB NSCLC: A Report of Toxicities and Clinical Respo...

Por Rengan, R., Mick, R., Pryma, D., Rosen, M.A., Lin, L., Maity, A., Evans, T. L., Stevenson, J. P., Langer, C.J., Kucharczuk, J., Friedberg, J., Prendergast, S., Sharkoski, T., Hahn, S.M.
Publicado em 2012

A phase II study of halichondrin B analogue eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California Cancer Con...

Por Gitlitz, Barbara J, Tsao-Wei, Denice D, Groshen, Susan, Davies, Angela, Koczywas, Marianna, Belani, Chandra P, Argiris, Athanassios, Ramalingam, Suresh, Vokes, Everett E, Edelman, Martin, Hoffman, Philip, Ballas, Marc S, Liu, Stephen V, Gandara, David R
Publicado em 2012